Academic literature on the topic 'Months plus'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Months plus.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Months plus"
1
Bolis, G., G. Favalli, S. Danese, et al. "Weekly cisplatin given for 2 months versus cisplatin plus cyclophosphamide given for 5 months after cytoreductive surgery for advanced ovarian cancer." Journal of Clinical Oncology 15, no. 5 (1997): 1938–44. http://dx.doi.org/10.1200/jco.1997.15.5.1938.
Full textAbstract:
PURPOSE To compare the efficacy of a treatment with cisplatin plus cyclophosphamide given for 5 months and a short treatment with cisplatin alone in advanced ovarian cancer, we conducted a multicenter randomized clinical trial. PATIENTS AND METHODS Eligibility criteria were as follows: first diagnosis of histologically confirmed invasive epithelial ovarian cancer of International Federation of Gynecology and Obstetric (FIGO) stage III-IV, age younger than 75 years, and Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2. Within 28 days of cytoreductive surgery, eligible women were randomly assigned treatment with weekly cisplatin 50 mg/m2 for nine courses or cisplatin 75 mg/m2 plus cyclophosphamide 750 mg/m2 every 21 days for six courses. RESULTS A total of 607 women were entered onto the study. There was no difference in the response to treatment. Pathologic complete response (CR) was documented in 63 of the weekly cisplatin cases and 70 of the cisplatin plus cyclophosphamide group (chi 1(2) = 1.43; P = .23). The median follow-up time was 3 years. There were 151 and 148 deaths in the weekly cisplatin and cyclophosphamide plus cisplatin arms, respectively. Survival curves were similar in the two groups, with a 3-year percent survival estimate of 44.1 (SE = 3.4) in the weekly cisplatin and 44.6 (SE = 3.4) in the cisplatin plus cyclophosphamide group (log-rank test chi 1(2) = 0.004; P = .96). CONCLUSION This study found that 2-month monochemotherapy treatment with cisplatin was as effective as 5-month polychemotherapy including cisplatin at a similar doses but different dose-intensity plus cyclophosphamide.
2
Limon, D., F. Bokstein, D. Blumenthal, C. Ben Harush, Z. Ram, and R. Grossman. "P14.79 Randomized phase II trial of Tumor Treating Fields plus radiation therapy plus temozolomide compared to radiation therapy plus temozolomide in patients with newly diagnosed glioblastoma." Neuro-Oncology 21, Supplement_3 (2019): iii86. http://dx.doi.org/10.1093/neuonc/noz126.314.
Full textAbstract:
Abstract BACKGROUND In last decade, there were numerous attempts to improve the outcome of patients with glioblastoma (GBM), but even after maximal surgical resection, radiation therapy (RT) and temozolomide (TMZ), followed by maintenance TMZ for 6 months the median OS is 14.6 months. In the EF-14 Phase III trial, the addition of Tumor Treating Fields (TTFields) at 200 kHz to maintenance TMZ increased the median OS to 20.9 months, compared with 16.0 months with maintenance TMZ alone (HR, 0.63; 95% CI, 0.53–0.76; p<0.001). Based on these results, the currently accepted standard of care for newly diagnosed GBM (ndGBM) is surgical resection if safely feasible, followed by RT with concomitant TMZ, and then followed by maintenance TMZ in combination with TTFields. Preclinical investigations have shown a radio-sensitizing effect of TTFields on glioma cells, suggesting synergistic effects between TTFields and radiotherapy. In a pilot study of 10 patients with ndGBM, we demonstrated that there was no increased treatment-related toxicity when TTFields were given in combination with RT/TMZ. The only TTFields-related adverse event was skin toxicity below the arrays. Preliminary progression free survival (PFS) data was encouraging. Based on the results of the pilot study, we designed this prospective, randomized Phase II study to further investigate if the addition of TTFields TMZ/RT treatment in ndGBM patients improves treatment efficacy and delays disease progression. MATERIAL AND METHODS Following debulking surgery or biopsy, 60 adult patients (≥18 years) with histologically confirmed GBM, KPS≥70 and life expectancy of at least 3 months will be randomized 1:1 to either a) RT with concomitant TMZ and TTFields (200 kHz) for 6 weeks followed by up to 6 months of maintenance TMZ in combination with TTFields (experimental arm) up to 24 months; or b) RT with concomitant TMZ alone followed by maintenance TMZ in combination with TTFields (control arm). Exclusion criteria: patients with early progressive disease, significant comorbidities precluding maintenance RT or TMZ or patients with an implanted electronic device. The primary endpoint is progression free survival at 12 months (PFS12). Treatment with TTFields will be continued until second progression or 24 months (the earlier of the two). All patients will be followed for survival. Grading and severity of all adverse events will be recorded using CTCAE V5.0. The sample size of 60 patients provides 80% power with a two-sided alpha level of 0.05 to detect a PFS12 of 46.5% with RT/TMZ/TTFields compared to 29.4% with RT/TMZ followed, respectively, by maintenance TMZ/TTFields (calculated from the RT/TMZ followed by maintenance TMZ/TTFields arm of the EF-14 trial). It is forecasted to take 24 months to fully recruit. Follow-up will continue for >12 months from recruitment of the last patient.
3
Grossman, Rachel, Dror Limon, Felix Bokstein, Carmit Ben Harosh, Deborah Blumenthal, and Zvi Ram. "RTID-12. PHASE 2 TRIAL OF TUMOR TREATING FIELDS (TTFIELDS) PLUS RADIATION THERAPY (RT) PLUS TEMOZOLAMIDE (TMZ) COMPARED TO RT PLUS TEMOZOLOMIDE IN NEWLY DIAGNOSED GLIOBLASTOMA (ndGBM)." Neuro-Oncology 22, Supplement_2 (2020): ii196. http://dx.doi.org/10.1093/neuonc/noaa215.817.
Full textAbstract:
Abstract OBJECTIVE In the EF-14 phase 3 trial, TTFields 9200 kHz) added to maintenance TMZ increased median OS to 20.9 months versus 16.0 months with maintenance TMZ (p&lt; 0.001) in ndGBM. Preclinical investigations showed that TTFields/RT have a synergistic effect. A pilot study (N=10) in ndGBM demonstrated the feasibility and safety of TTFields combined with RT/TMZ (Grossman Front Onc 2020). The only TTFields-related adverse event was array-associated skin toxicity. Median PFS was 8.9 months. Based on these encouraging results, this prospective, randomized phase 2 study [NCT03869242] in 60 patients further investigates if the addition of TTFields TMZ/RT treatment in ndGBM patients improves treatment efficacy and delays disease progression. METHODS Following debulking surgery or biopsy, 60 patients (≥18 years) with histologically confirmed GBM, KPS≥70 and life expectancy &gt;3 months will be randomized 1:1 to: i) RT with concomitant TMZ/TTFields (200 kHz) for 6 weeks followed by up to 6 months of maintenance TMZ combined with TTFields (experimental arm) up to 24 months; or ii) RT with concomitant TMZ alone followed by maintenance TMZ combined with TTFields (control arm). Patients with early progressive disease, significant comorbidities precluding maintenance RT or TMZ or with implanted electronic devices will be excluded. The primary endpoint is the rate of progression free survival at 12 months (PFS12). Treatment with TTF will be continued until second progression or 24 months (the earlier of the two). All patients will be followed for survival. All adverse events will graded per CTCAE V5.0. The sample size of 60 patients provides 80% power with two-sided alpha level of 0.05 to detect a PFS12 of 46.5% with RT/TMZ/TTFields compared to 29.4% with RT/TMZ followed, respectively, by maintenance TMZ/TTFields (calculated from the RT/TMZ followed by maintenance TMZ/TTFields arm of the EF-14 trial). Follow-up will continue for &gt;12 months from recruitment of the last patient.
4
Chiorean, E. Gabriela, Scott Whiting, Gary Binder, George Dranitsaris, and Victoria Manax. "Cost-effectiveness of nab-paclitaxel plus gemcitabine versus erlotinib plus gemcitabine in metastatic pancreatic cancer." Journal of Clinical Oncology 32, no. 3_suppl (2014): 353. http://dx.doi.org/10.1200/jco.2014.32.3_suppl.353.
Full textAbstract:
353 Background: In a recent phase III trial nab-paclitaxel (albumin-bound paclitaxel) + gemcitabine (nab-P/G) demonstrated a 1.8 month, or 27%, improvement in median overall survival (OS) (HR = 0.72, P < 0.001) vs gemcitabine (G) in first-line metastatic pancreatic cancer (mPC). nab-P/G had higher 1 year OS (35% vs 22%) and improved PFS by 1.8 months (HR = 0.69, P < 0.01). nab-P/G is the first taxane based therapy to show a significant OS improvement in a phase III mPC trial. Erlotinib + gemcitabine (E/G) has also demonstrated activity in mPC, with a 0.3 month OS benefit vs G (HR = 0.82, P = 0.04), a 1 year OS of 23% vs 17%, and 0.2 months PFS benefit (HR = 0.77, P = 0.004) vs G. A cost-effectiveness analysis measuring the cost per life year (LY) gained for nab-P/G and E/G was conducted from the US payer perspective. Methods: Costs and clinical outcomes were evaluated fromnab-P/G vs G and E/G vs G trials of mPC. Health care resource use and the management of grade III/IV adverse events (AE) were collected from a large multisite US oncology clinic, expert opinion, and literature (2012 US dollars). Drug cost per cycle was multiplied by the median cycles delivered from the trials for nab-P/G and E/G. Results: Duration of therapy was 4 months for nab-P/G vs 3.9 months for E/G. Total cost for nab-P/G was $24,984 vs $23,044 for E/G, including drug, administration and AE management. AE costs were similar between the two therapies (Table). Differences of > 5% were noted in neutropenia (rates: nab-P/G = 33%; E/G = 24%), neuropathy (nab-P/G = 17%; E/G = 1%), and rash (nab-P/G = 0%; E/G = 6%). The net survival advantage for nab-P/G vs E/G was 1.5 incremental life months gained. Nab-P/G was cost-effective relative to E/G, at a cost of $15,522 per incremental life year gained. Conclusions: nab-P/G is a cost-effective alternative to E/G in mPC, bringing more months of OS at < $16,000 cost per incremental life year gained. [Table: see text]
5
O'Connell, M. J., J. A. Laurie, M. Kahn, et al. "Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer." Journal of Clinical Oncology 16, no. 1 (1998): 295–300. http://dx.doi.org/10.1200/jco.1998.16.1.295.
Full textAbstract:
PURPOSE This study had two major goals: (1) to assess the effectiveness of a regimen of fluorouracil (5-FU) plus levamisole plus leucovorin as postoperative surgical adjuvant therapy for patients with high-risk colon cancer, and (2) to evaluate 6 months versus 12 months of chemotherapy. PATIENTS AND METHODS Patients with poor-prognosis stage II or III colon cancer were randomly assigned to receive adjuvant chemotherapy with either intensive-course 5-FU and leucovorin combined with levamisole, or a standard regimen of 5-FU plus levamisole. Patients were also randomly assigned to receive either 12 months or 6 months of chemotherapy, which resulted in four treatment groups. RESULTS Eight hundred ninety-one of 915 patients entered (97.4%) were eligible. The median follow-up duration is 5.1 years for patients still alive. There was a difference among the four treatment groups with respect to patient survival, and a significant duration-by-regimen interaction was observed. Specifically, standard 5-FU plus levamisole was inferior to 5-FU plus leucovorin plus levamisole when treatment was given for 6 months (5-year survival rate, 60% v 70%; P < .01). CONCLUSION There was no significant improvement in patient survival when chemotherapy was given for 12 months compared with 6 months. When chemotherapy was given for 6 months, standard 5-FU plus levamisole was associated with inferior patient survival compared with intensive-course 5-FU plus leucovorin plus levamisole. These data suggest that 5-FU plus levamisole for 6 months should not be used in clinical practice, whereas 6 months of treatment with 5-FU plus leucovorin plus levamisole is effective.
6
Hensley, Martee L., Austin Miller, David M. O'Malley, et al. "Randomized Phase III Trial of Gemcitabine Plus Docetaxel Plus Bevacizumab or Placebo As First-Line Treatment for Metastatic Uterine Leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group Study." Journal of Clinical Oncology 33, no. 10 (2015): 1180–85. http://dx.doi.org/10.1200/jco.2014.58.3781.
Full textAbstract:
Purpose Fixed-dose rate gemcitabine plus docetaxel achieves objective response in 35% of patients with uterine leiomyosarcoma (uLMS). This study aimed to determine whether the addition of bevacizumab to gemcitabine-docetaxel increases progression-free survival (PFS) in uLMS. Patients and Methods In this phase III, double-blind, placebo-controlled trial, patients with chemotherapy-naive, metastatic, unresectable uLMS were randomly assigned to gemcitabine-docetaxel plus bevacizumab or gemcitabine-docetaxel plus placebo. PFS, overall survival (OS), and objective response rates (ORRs) were compared to determine superiority. Target accrual was 130 patients to detect an increase in median PFS from 4 months (gemcitabine-docetaxel plus placebo) to 6.7 months (gemcitabine-docetaxel plus bevacizumab). Treatment effects on PFS and OS were described by hazard ratios (HRs), median times to event, and 95% CIs. Results In all, 107 patients were accrued: gemcitabine-docetaxel plus placebo (n = 54) and gemcitabine-docetaxel plus bevacizumab (n = 53). Accrual was stopped early for futility. No statistically significant differences in grade 3 to 4 toxicities were observed. Median PFS was 6.2 months for gemcitabine-docetaxel plus placebo versus 4.2 months for gemcitabine-docetaxel plus bevacizumab (HR, 1.12; P = .58). Median OS was 26.9 months for gemcitabine-docetaxel plus placebo and 23.3 months for gemcitabine-docetaxel plus bevacizumab (HR, 1.07; P = .81). Objective responses were observed in 17 (31.5%) of 54 patients randomly assigned to gemcitabine-docetaxel plus placebo and 19 (35.8%) of 53 patients randomly assigned to gemcitabine-docetaxel plus bevacizumab. Mean duration of response was 8.6 months for gemcitabine-docetaxel plus placebo versus 8.8 months for gemcitabine-docetaxel plus bevacizumab. Conclusion The addition of bevacizumab to gemcitabine-docetaxel for first-line treatment of metastatic uLMS failed to improve PFS, OS, or ORR. Gemcitabine-docetaxel remains a standard first-line treatment for uLMS.
7
Rao, Sheela, Francesco Sclafani, Cathy Eng, et al. "International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct." Journal of Clinical Oncology 38, no. 22 (2020): 2510–18. http://dx.doi.org/10.1200/jco.19.03266.
Full textAbstract:
PURPOSE To compare cisplatin plus fluorouracil (FU) versus carboplatin plus paclitaxel in chemotherapy-naïve advanced anal cancer to establish the optimal regimen. PATIENTS AND METHODS Patients who had not received systemic therapy for advanced anal cancer were randomly assigned 1:1 to intravenous cisplatin 60 mg/m2 (day 1) plus FU 1,000 mg/m2 (days 1-4) every 21 days or carboplatin (area under the curve, 5; day 1) plus paclitaxel 80 mg/m2 (days 1, 8, and 15) every 28 days for 24 weeks, until disease progression, intolerable toxicity, or withdrawal of consent. Primary end point was objective response rate (ORR). Primary and secondary end points were assessed in a hierarchic model to compare the regimens and pick the winner. RESULTS We conducted an international multicenter randomized phase II study in 60 centers between December 2013 and November 2017. Median follow-up was 28.6 months. A total of 91 patients were randomly assigned: 46 to cisplatin plus FU and 45 to carboplatin plus paclitaxel. ORR was 57% (95% CI, 39.4% to 73.7%) for cisplatin plus FU versus 59% (95% CI, 42.1% to 74.4%) for carboplatin plus paclitaxel. More serious adverse events were noted in the cisplatin plus FU arm (62%) compared with the carboplatin plus paclitaxel arm (36%; P = .016). Median progression-free survival was 5.7 months (95% CI, 3.3 to 9.0 months) for cisplatin plus FU compared with 8.1 months (95% CI, 6.6 to 8.8 months) for carboplatin plus paclitaxel. Median overall survival was 12.3 months for cisplatin plus FU (95% CI, 9.2 to 17.7 months) compared with 20 months (95% CI, 12.7 months to not reached) for carboplatin plus paclitaxel (hazard ratio, 2.00; 95% CI, 1.15 to 3.47; P = .014). CONCLUSION This is the first international randomized trial to our knowledge conducted in chemotherapy-naïve advanced anal cancer. Although there was no difference in ORR, the association with clinically relevant reduced toxicity and a trend toward longer survival suggest that carboplatin plus paclitaxel should be considered as a new standard of care.
8
Berthold, Dominik R., Gregory R. Pond, Freidele Soban, Ronald de Wit, Mario Eisenberger, and Ian F. Tannock. "Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study." Journal of Clinical Oncology 26, no. 2 (2008): 242–45. http://dx.doi.org/10.1200/jco.2007.12.4008.
Full textAbstract:
Purpose The TAX 327 study compared docetaxel administered every 3 weeks (D3), weekly docetaxel (D1), and mitoxantrone (M), each with prednisone (P), in 1,006 men with metastatic hormone-resistant prostate cancer (HRPC). The original analysis, undertaken in August 2003 when 557 deaths had occurred, showed significantly better survival and response rates for pain, prostate-specific antigen (PSA), and quality of life for D3P when compared with MP. Here, we report an updated analysis of survival. Methods Investigators were asked to provide the date of death or last follow-up for all participants who were alive in August 2003. Results By March 2007, data on 310 additional deaths were obtained (total = 867 deaths). The survival benefit of D3P compared with MP has persisted with extended follow-up (P = .004). Median survival time was 19.2 months (95% CI, 17.5 to 21.3 months) in the D3P arm, 17.8 months (95% CI, 16.2 to 19.2 months) in the D1P arm, and 16.3 months (95% CI, 14.3 to 17.9 months) in the MP arm. More patients survived ≥ 3 years in the D3P and D1P arms (18.6% and 16.6%, respectively) compared with the MP arm (13.5%). Similar trends in survival between treatment arms were seen for men greater than and less than 65 years of age, for those with and without pain at baseline, and for those with baseline PSA greater than and less than the median value of 115 ng/mL. Conclusion The present analysis confirms that survival of men with metastatic HRPC is significantly longer after treatment with D3P than with MP. Consistent results are observed across subgroups of patients.
9
Emery, Paul, Gerd R. Burmester, Vivian P. Bykerk, et al. "Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period." Annals of the Rheumatic Diseases 74, no. 1 (2014): 19–26. http://dx.doi.org/10.1136/annrheumdis-2014-206106.
Full textAbstract:
ObjectivesTo evaluate clinical remission with subcutaneous abatacept plus methotrexate (MTX) and abatacept monotherapy at 12 months in patients with early rheumatoid arthritis (RA), and maintenance of remission following the rapid withdrawal of all RA treatment.MethodsIn the Assessing Very Early Rheumatoid arthritis Treatment phase 3b trial, patients with early active RA were randomised to double-blind, weekly, subcutaneous abatacept 125 mg plus MTX, abatacept 125 mg monotherapy, or MTX for 12 months. Patients with low disease activity (Disease Activity Score (DAS)28 (C reactive protein (CRP)) <3.2) at month 12 entered a 12-month period of withdrawal of all RA therapy. The coprimary endpoints were the proportion of patients with DAS28 (CRP) <2.6 at month 12 and both months 12 and 18, for abatacept plus MTX versus MTX.ResultsPatients had <2 years of RA symptoms, DAS28 (CRP) ≥3.2, anticitrullinated peptide-2 antibody positivity and 95.2% were rheumatoid factor positive. For abatacept plus MTX versus MTX, DAS28 (CRP) <2.6 was achieved in 60.9% versus 45.2% (p=0.010) at 12 months, and following treatment withdrawal, in 14.8% versus 7.8% (p=0.045) at both 12 and 18 months. DAS28 (CRP) <2.6 was achieved for abatacept monotherapy in 42.5% (month 12) and 12.4% (both months 12 and 18). Both abatacept arms had a safety profile comparable with MTX alone.ConclusionsAbatacept plus MTX demonstrated robust efficacy compared with MTX alone in early RA, with a good safety profile. The achievement of sustained remission following withdrawal of all RA therapy suggests an effect of abatacept's mechanism on autoimmune processes.Trial registration numberNCT01142726.
10
Marzano, Raffaele, Nicola Dinelli, Valeria Ales, and Maria Antonella Bertozzi. "Effectiveness on urinary symptoms and erectile function of Prostamev Plus® vs only extract Serenoa repens." Archivio Italiano di Urologia e Andrologia 87, no. 1 (2015): 25. http://dx.doi.org/10.4081/aiua.2015.1.25.
Full textAbstract:
Prostatic inflammation is widespread in the male population. Two groups of 50 patients each with symptoms of prostatic inflammation and ecocolorDoppler indicative of prostatitis were identified. Both groups were further subdivided into two subgroups (respectively A1, A2, B1, and B2). Group A1 underwent therapy with oral levofloxacin 500 mg daily for 10 days plus co-treatment with oral Serenoa repens (320 mg) plus Bromeline plus Nettle (Prostamev Plus®) daily for two months; Group A2 with oral levofloxacin 500 mg daily for 10 days plus oral Serenoa repens extract 320 mg/day for two months; Group B1 specific antibiotic treatment for 10 days (included levofloxacin if sensitive) plus co-treatment with oral Serenoa repens (320 mg) plus Bromeline plus Nettle (Prostamev Plus®) daily for two months; Group B2 with specific antibiotic treatment for 10 days plus Serenoa repens 320 mg/day for two months. The groups treated with Prostamev Plus® in comparison to the groups treated with Serenoa repens extract (saw palmetto) achieved better improvements of both IPSS score, urinary flow and sexual life.
Dissertations / Theses on the topic "Months plus"
1
Tsonis, Mary. "Perception of texture during unimodal haptic and bimodal haptic-plus-visual conditions in 3- and 6-month-old infants." Thesis, 2002. http://spectrum.library.concordia.ca/2348/1/NQ73352.pdf.
Full textAbstract:
The importance of the haptic system (cutaneous and kinaesthetic processes) in development is widely acknowledged. Yet little is known about infants' haptic perceptual abilities during the first half-year of life. This is due, in part, to the view that haptic perceptual abilities are limited prior to the development of fine-motor exploratory skills and visual prehension. The methodology of existing studies (e.g., the visibility of stimuli and confounding properties, selection of stimuli, and fixed-trials habituation procedures) has also limited clear interpretations with respect to infants' haptic perception. The present research consisted of two studies designed to assess early haptic perceptual abilities by employing a stimulus property salient to this system, texture. Study 1 examined unimodal haptic perception at 3 and 6 months of age, just before and after gains in fine-motor and visual prehension are made. Vision was occluded by an opaque plastic cover and the textures were presented underneath the cover to infants' hands. An infant-controlled Habituation (HAB)-Novelty (NOV)-Return-to-Familiar (RFAM) procedure was employed. Following habituation, experimental group infants received a novel texture for 3 NOV test trials and the original texture for 3 RFAM test trials. Control group infants received the same HAB texture during all test trials. Study 2 was designed to assess the influence of vision on haptic perception of texture. Using the same textures as in Study 1 and presenting them under a transparent cover, infants were permitted both haptic and visual exploration during the HAB phase. However, the test phases were unimodal haptic. Results of infants' haptic manipulations indicated that both 3- and 6-month-olds habituated following similar amounts of haptic manipulation, and that levels of haptic manipulation to habituation did not differ across Studies 1 and 2. In addition, infants discriminated novel textures during NOV, and recognized the original texture during RFAM in both studies. These results suggest that haptic perception and discrimination of texture may not be dependent on visual guidance. However, infants in Study 2 haptically manipulated for shorter amounts of time during NOV and RFAM, relative to Study l, suggesting that the visual input during HAB may have facilitated discrimination and recognition of textures. Facilitation effects may reflect the integration of visual and haptic input during HAB and the detection of amodal relations across haptics and vision. Vision also suppressed the novelty responses observed in Study 1 on the measure of exploratory procedures (EPs). The EPs may have been suppressed by the lack of salient visual features, again suggesting that visual and haptic input was integrated. Suppression of EPs was less pronounced for the 6-, relative to 3-month-olds, who engaged in more EPs in response to the rough texture in both studies, suggesting that among infants with more developed fine-motor skills, the haptic features of stimuli may alone elicit exploration in this modality. Overall, the findings: (1) support haptic perception of texture during the first half-year of life; (2) suggest an important and unique role for haptics in early perceptual learning; and (3) contribute to the understanding of infants' haptic perception during bimodal exploration. The methodological contributions of the present studies in accessing infants' haptic abilities are discussed and future research directions are proposed.
Books on the topic "Months plus"
1
Adams, Robert A. Calculus: A complete course plus mymathlab global 24 months student access card. Pearson, 2010.
Find full text
3
Lei, Ying. SSP Plus at 36 months: Effects of adding employment services to financial work incentives. Social Research and Demonstration Corporation, 2001.
Find full text
4
Ying, Lei. SSP Plus at 36 months: Effects of adding employment services to financial work incentives. Social Research and Demonstration Corp., 2001.
Find full text
5
Lei, Ying. SSP plus at 36 months: Effects of adding employment services to financial work incentives. Social Research and Demonstration Corporation, 2001.
Find full text
6
MacNaughton, Robin. Selections from Robin MacNaughton's sun sign personality guide: Plus a month-by-month astrology guide. Bantam, 1987.
Find full text
9
Ekrutt, Joachim W. Stars: 60 photos, maps, charts, and drawings : star charts for each month of the year, updated to 1999, diagrams of major constellations, plus facts and figures for amateur astronomers. 2nd ed. Barron's, 1995.
Find full text
10
Liskin-Gasparro, Judith E., Paloma Lapuerta, and Elizabeth Guzman. Unidos Plus MySpanishLab (24 Months). Pearson Education, 2012.
Find full textBook chapters on the topic "Months plus"
1
Weight, Christopher. "Nephrectomy Followed by Interferon Alfa-2b Compared With Interferon Alfa-2b Alone for Metastatic Renal Cell Cancer." In 50 Studies Every Urologist Should Know. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780190655341.003.0020.
Full textAbstract:
This chapter summarizes the findings of a landmark trial of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma performed in the interferon era. All enrolled patients had a good performance status. It found overall survival extended by about 3 months in the cytoreductive-nephrectomy-plus-interferon arm versus the interferon-only arm.
2
Miles, Merrick E., and Avinash B. Kumar. "Decompressive Craniectomy in Diffuse Traumatic Brain Injury." In 50 Studies Every Intensivist Should Know, edited by Edward A. Bittner and Michael E. Hochman. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190467654.003.0002.
Full textAbstract:
The Decompressive Craniectomy in Diffuse Traumatic Brain Injury or DECRA trial was the first neurosurgical randomized controlled trail that sought to answer whether decompressive craniectomies (DC) improved patient outcomes after severe diffuse traumatic brain injury (TBI). The trial was conducted over a decade in centers across New Zealand, Saudi Arabia, and Australia, and the results were published in 2011; 155 patients were randomized to two cohorts, the medical management cohort and the medical management plus DC cohort. The primary endpoint was the functional outcomes, measured at 6 months post discharge. The results of the trial were somewhat unanticipated. In spite of achieving superior ICP control and intensive care outcomes, the DC cohort had worse long-term outcomes. The DECRA trial raised several questions and criticisms that currently preclude us from drawing broad conclusions about the efficacy of DC in diffuse TBI.
3
Einsele, Hermann, and Peter J. Maddison. "Multicentric reticulohistiocytosis." In Oxford Textbook of Rheumatology. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0169.
Full textAbstract:
Multicentric reticulohistiocytosis (MRH) is a rare systemic disease characterized by the combination of typical papular and nodular skin lesions and a severe and destructive polyarthritis, although virtually any organ system of the body can be involved. MRH most commonly affects middle-aged white women; it is about three times more common in women with a mean age at onset in the fifth decade. MRH is a rare histiocytic proliferative disease of unknown aetiology, characterized by tissue infiltration by histiocytes and multinuclear giant cells. The stimulus for the histiocytic proliferation has not been fully elucidated, although there is an association with internal malignancies and abnormal immunological laboratory findings. The diagnosis is confirmed by skin or synovial biopsy. The disease often runs a waxing and waning course and sometimes stabilizes. Work-up for underlying malignancy cannot be overemphasized. The recommended treatment for MRH is oral methrotrexate plus prednisone tapered gradually over 3–4 months.
4
Peponis, Thomas, and David R. King. "Intracranial Pressure Monitoring in Severe Traumatic Brain Injury." In 50 Studies Every Intensivist Should Know, edited by Edward A. Bittner and Michael E. Hochman. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190467654.003.0007.
Full textAbstract:
The study “A Trial of Intracranial-Pressure Monitoring in Traumatic Brain Injury” published by Chesnut et al. aimed to resolve the debatable issue of the benefit of intracranial-pressure (ICP) monitoring in patients with severe traumatic brain injury (TBI). The authors designed a randomized controlled trial that was conducted in Latin America. A total of 324 patients admitted with severe TBI were randomly assigned to two groups. The first group (n = 157) was managed with ICP monitoring, using an intraparenchymal monitor. The goal was to keep the ICP below 20 mm Hg. Management of patients comprising the second group (n = 167) was based solely on serial clinical examinations and imaging tests. It was hypothesized that ICP-monitoring would result in increased survival rates, plus improved functional and neuropsychological status at 6-months after the injury. Additionally, the authors hypothesized that complication rates would be decreased and the ICU length of stay shorter.
5
Pool, Robert. "Business." In Beyond Engineering. Oxford University Press, 1997. http://dx.doi.org/10.1093/oso/9780195107722.003.0008.
Full textAbstract:
In January 1975, the magazine Popular Electronics trumpeted the beginnings of a revolution. “Project Breakthrough,” the cover said: “World’s First Minicomputer Kit to Rival Commercial Models.” Inside, a six-page article described the Altair, an unassembled computer that could be ordered from MITS, a company in Albuquerque originally founded to sell radio transmitters for controlling model airplanes. To the uninitiated, it didn’t look like much of a revolution. For $397 plus shipping, a hobbyist or computer buff could get a power supply, a metal case with lights and switches on the front panel, and a set of integrated circuit chips and other components that had to be soldered into place. When everything was assembled, a user gave the computer instructions by flipping the panel’s seventeen switches one at a time in a carefully calculated order; loading a relatively simple program might involve thousands of flips. MITS had promised that the Altair could be hooked up to a Teletype machine for its input, but the circuit boards needed for the hookup wouldn’t be available for a number of months. To read the computer’s output, a user had to interpret the on/off pattern of flashing lights; it would be more than a year before MITS would offer an interface board to transform the output into text or figures on a television screen. And the computer had no software. A user had to write the programs himself in arcane computer code or else borrow the efforts of other enthusiasts. One observer of the early computer industry summed up the experience like this: “You buy the Altair, you have to build it, then you have to build other things to plug into it to make it work. You are a weird-type person. Because only weird-type people sit in kitchens and basements and places all hours of the night, soldering things to boards to make machines go flickety-flock.” But despite its shortcomings, several thousand weird-type people bought the Altair within a few months of its appearance. What inspired and intrigued them was the semiconductor chip at the heart of the computer.
6
Anderson, Garnet L., and Ross L. Prentice. "Understanding the Effects of Menopausal Hormone Therapy: Using the Women’s Health Initiative Randomized Trials and Observational Study to Improve Inference." In Causality and Psychopathology. Oxford University Press, 2011. http://dx.doi.org/10.1093/oso/9780199754649.003.0009.
Full textAbstract:
Over the last decade, several large-scale randomized trials have reported results that disagreed substantially with the motivating observational studies on the value of various chronic disease–prevention strategies. One high-profile example of these discrepancies was related to postmenopausal hormone therapy (HT) use and its effects on cardiovascular disease and cancer. The Women’s Health Initiative (WHI), a National Heart, Lung, and Blood Institute–sponsored program, was designed to test three interventions for the prevention of chronic diseases in postmenopausal women, each of which was motivated by a decade or more of analytic epidemiology. Specifically, the trials were testing the potential for HT to prevent coronary heart disease (CHD), a low-fat eating pattern to reduce breast and colorectal cancer incidence, and calcium and vitamin D supplements to prevent hip fractures. Over 68,000 postmenopausal women were randomized to one, two, or all three randomized clinical trial (CT) components between 1993 and 1998 at 40 U.S. clinical centers (Anderson et al., 2003a). The HT component consisted of two parallel trials testing the effects of conjugated equine estrogens alone (E-alone) among women with prior hysterectomy and the effect of combined estrogen plus progestin therapy (E+P), in this case conjugated equine estrogens plus medroxyprogesterone acetate, among women with an intact uterus, on the incidence of CHD and overall health. In 2002, the randomized trial of E+P was stopped early, based on an assessment of risks exceeding benefits for chronic disease prevention, raising concerns among millions of menopausal women and their care providers about their use of these medicines. The trial confirmed the benefit of HT for fracture-risk reduction but the expected benefit for CHD, the primary study end point, was not observed. Rather, the trial results documented increased risks of CHD, stroke, venous thromboembolism (VTE), and breast cancer with combined hormones (Writing Group for the Women’s Health Initiative Investigators, 2002). Approximately 18 months later, the E-alone trial was also stopped, based on the finding of an adverse effect on stroke rates and the likelihood that the study would not confirm the CHD-prevention hypothesis.
7
Aldrin, Philippe, and Nicolas Hubé. "Conclusion. La politique n’est plus ce qu’elle était, la communication non plus." In Les mondes de la communication publique. Presses universitaires de Rennes, 2014. http://dx.doi.org/10.4000/books.pur.71822.
Full text
8
Ilunga-Ilunga, Félicien, Alain Levêque, Vévé Mbuyi Kanyinda, Jean Paul Mbikayi Muya, and Michèle Dramaix. "Malaria Lethality in Children under 5 Years of Age and Study of Risk Factors in MbujiMayi Paediatric Environment, a Neglected Deadly Epidemic in the Democratic of Republic of Congo." In Current Topics and Emerging Issues in Malaria Elimination. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.98511.
Full textAbstract:
The objective of this study was to determine the risk factors for malaria lethality in the MbujiMayi paediatric environment, a follow-up study of hospitalised cases over 5 years was conducted between January 2016 and December 2020 in the four hospitals. The case rate was 6.9% for the total (139 cases of death for 2017 cases of severe malaria for 5 years,) and varied from year to year (10.7% in 2016 to 4.6% in 2020). Cox Proportional Risk Model results including significant covariates in multivariate analysis [HR (IC95%)]. In multivariate analysis, two models were considered. The case-fatality rate was independently associated with late arrival after 48 hours [3.1 (1.9–5.1); p < 0.001], types of pre-hospital recourse such as recourse to the church [1.4 (1.1–2.1),; p = 0.042) and tradipractor [3.2 (1.8–6.1); p < 0.001] for severe malaria, children under 12 months of age [1.8 (1.2–2.8); p < 0.001], those with circulatory collapse [2.6 (1.1–6.1); p < 0.001] and those in deep coma [1.9 (1.1–3.4); p = 0.016]. The second model with the number of associated syndromes, showed that the risk was 1.7 plus for children with a complex clinical picture, made up of the combination of several signs [1.7 (1.1–2.6); p < 0.001]. These results highlight the need for more information campaigns to encourage people to seek institutional care for malaria. Our results also suggest that prophylactic treatment may be advisable for children under 5 years of age.
9
Paykina, Natalya, Laurence L. Greenhill, and Jack M. Gorman. "Pharmacological Treatments for Attention-Deficit/Hyperactivity Disorder." In A Guide to Treatments that Work. Oxford University Press, 2007. http://dx.doi.org/10.1093/med:psych/9780195304145.003.0002.
Full textAbstract:
More than 225 placebo-controlled Type 1 investigations demonstrate that psychostimulants—a group of ethylamines including methylphenidate and amphetamine—are highly effective in reducing core symptoms of childhood attention-deficit/hyperactivity disorder (ADHD) in preschoolers, school-age children, adolescents, and adults. Approximately 70% of patients respond to these medications in double-blind trials compared with 13% assigned to placebo. Short-term efficacy is more pronounced for behavioral rather than cognitive and learning abnormalities associated with ADHD. The stimulant treatment evidence base has been supplemented by two large multisite randomized controlled trials (RCTs)—the Multimodal Treatment Study of ADHD (MTA Study) and the Preschool ADHD Treatment Study (PATS)—that further support the short-term efficacy in young children. This study, plus the 1998 NIH Consensus Development Conference on ADHD, and the publication of the McMaster Evidence Based Review of ADHD Treatments (Jahad et al., 1999) emphasized the large evidence base supporting the efficacy of stimulant treatments. These medications are now available in long-duration preparations that allow for once-daily oral dosing, and they may even be sprinkled on food to accommodate children who cannot swallow pills. RCTs conducted more recently than 1998 continue to report a few key adverse events associated with stimulants—insomnia, decreased appetite, stomachache, and headache—but have not supported rarer and unexpected problems, such as visual hallucinations, cardiovascular accidents, or sudden unexpected death, reported anecdotally in the Food and Drug Administration’s Adverse Event Report System (AERS) MedWatch. Although these ADHD medications have been shown to retain their efficacy for as long as 14 months, concern remains that the long-term academic and social benefits have not yet been adequately assessed. Other nonstimulant agents for which there is limited evidence of efficacy include atomoxetine, modafinil, the tricyclics, bupropion, clonidine, and venlafaxine.
10
Gilbertson, David, and Michael Durand. "Human Sickness and Mortality Rates in Relation to the Distant Eruption of Volcanic Gases: Rural England and the 1783 Eruption of the Laid Fissure, Iceland." In Geology and Health. Oxford University Press, 2003. http://dx.doi.org/10.1093/oso/9780195162042.003.0008.
Full textAbstract:
Chapter 3 explores an apparent relationship between human mortality in England and exposure to acid volatiles derived from the Laki fissure eruption of 1783. It has long been known that volcanic tephra and gases may be transported great distances (Thórarinsson 1981). Research into their impacts on human health and the environment has typically focused on populations and environments relatively close to the eruption (e.g. Oskarsson 1980, Rose 1977, Thórarinsson 1979). However, recent investigations of documentary sources such as diaries and newspapers have suggested that in particular meteorological situations, and where air masses are stable, profound health and environmental consequences may have occurred in the British Isles and elsewhere in Europe, at great distances from the volcanic source in Iceland (Brayshay and Grattan 1999, Dodgshon et al. 2000, Durand 2000, Durand and Grattan 1999, Grattan 1998 a and b, Grattan and Brayshay 1995, Grattan and Charman 1994, Grattan and Pyatt 1994, 1999, Grattan et al. 1998, Stothers 1996). This chapter presents and examines documentary evidence for human illness, which may have been induced by volcanogenic air pollution, and mortality in several widely dispersed villages in rural England in the late eighteenth century. Burial records for these settlements point to a singular peak in mortality in the summer of 1783, a period that is coincident with the peak concentration of volcanic gases from the Laki fissure in the European environment. The Laki fissure eruption took place between June 1783 and February 1784. It produced large quantities of acid volatiles — approximately ~120 Mt SO2, 6.8 Mt HC1, and 15.1 Mt HF plus H2S and NH3. Of the total compounds emitted, approximately 60% were emitted during the first few months of activity and the majority of these emissions were confined to the troposphere (Sparks et al. 1997,Thordarson et al. 1996, Thordarson and Self 1993). The eruption therefore generated the largest known air pollution event of the last two millennia (Stothers 1996) and, moreover, one that was entirely natural in origin. A series of stable high-pressure air masses were stationed over northwest Europe throughout the summer of 1783 (Kington 1988).
Conference papers on the topic "Months plus"
1
Pasha, Khalifa, and Rajeeva Kumar. "30 Days to 36 Months Plus Operation-Reliability Improvement Journey of Integrally Geared Compressors." In Abu Dhabi International Petroleum Exhibition & Conference. Society of Petroleum Engineers, 2020. http://dx.doi.org/10.2118/203002-ms.
Full text
2
King, Shelby, Sterling Hubbard, and Jenni Teeters. "An Interactive Personalized Feedback and Text-Messaging Intervention is Associated with Reductions in Substance-Impaired Driving." In 2020 Virtual Scientific Meeting of the Research Society on Marijuana. Research Society on Marijuana, 2021. http://dx.doi.org/10.26828/cannabis.2021.01.000.38.
Full textAbstract:
Background: Substance-impaired driving continues to be a national public health concern and data suggests that up to one-third of college students report driving after drinking and/or cannabis use in the past year. To date, little research has investigated whether brief, technology-based interventions can be used to reduce substance-impaired driving among young adults. Recent research indicates that interventions that incorporate personal contact lead to larger effect sizes than fully automated interventions. The present study compared an interactive text-messaging intervention to an automated text-messaging intervention in the context of a brief, mobile-phone based substance-impaired driving intervention. Method: Participants were recruited through the university’s subject pool (n = 46) and completed measures that assessed impaired driving at baseline and three-month follow-up. In order to be eligible, students had to be at least 18 years or older, have access to a motor vehicle, and report driving after drinking two or more drinks and/or driving after cannabis use at least three times in the past three months. Participants were randomly assigned into four conditions: personalized feedback plus text-messaging (n = 12), personalized feedback plus automated text messaging (n = 11), an active control condition- (substance use information, n = 12), and an assessment only control condition (n = 11). Results: Repeated measures ANOVAs were run to compare the number of times driving while impaired over time across conditions. Analyses revealed the personalized feedback plus text-messaging led to significantly greater reductions over time in the number of times driving while impaired compared to participants in the assessment-only condition (p = .022). Additionally, participants in the personalized feedback plus text-messaging condition reported a greater reduction over time in the number of times driving while impaired than those in the personalized feedback plus automated text messaging condition, though this difference was not significantly significant (p = .066). Surprisingly, the text-messaging conditions did not result in significantly greater reductions in substance-impaired driving compared to the active control condition (p = .227). Discussion: Overall, these findings provide preliminary support for the short-term efficacy of a mobile-delivered personalized feedback intervention with interactive text-messaging in reducing substance-impaired driving among young adults. Due to Covid-19, three-month follow-up data could not be collected from half of the originally enrolled sample, resulting in underpowered analyses. Additional data will be collected as part of this pilot trial in the coming year.
3
Boda, Z., G. Pfliegler, I. Tornai, M. Udvardy, J. Hársfalvi, and K. Rak. "LONG-TERM COUMAROL PLUS SMALL DOSE ASA THERAPY IN PATIENTS WITH PROSTHETIC HEART VALVE. SOME QUESTIONS OF LABORATORY CONTROL." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643268.
Full textAbstract:
Thromboembolism in patients with prosthetic heart valves remains a major time-related problem (Sullivan 1971, Dale 1976, Chesebro 1983). Patients receiving anticoagulant plus antiplatelet agent have the lowest incidence of thromboembolism but the risk of bleeding is not negligible. The laboratory control of combined therapy is unsolved.This study considers the thromboembolic prophylaxis of 38 patients with prosthetic heart valve. Cou-marol treatment was combined with ASA (1 000 mg/week, 36 months follow up).Prothrombin ratio was used in control of the oral anticoagulant therapy. Malondialdehyde production was measured parallel with the so-called malondialdehyde-ratio (MDA-ratio = malondialdehyde level of patient/ control plasma). MDA-ratio, platelet aggregation, thromboxane and prostacycline metabolites were studied 48 hours after 500 mg ASA intake. The average of MDA-ratio was 0.42 ± 0.23 (from 137 measurements). The therapeutic range of MDA-ratio is 0.7 - 0.2. Value below 0.2 means overdosed, over 0.7 means an ineffective ASA therapy. Normal first and second phase platelet aggregation was observed in 23 % of cases when MDA-ratio was below 0.5. Only in 4 % of patients with MDA-ratio over 0.7 was found an abnormal platelet aggregation. The mean prothrombin ratio was 1.59 ± 0.22.No gastrointestinal bleeding or thromboembolism was observed during the 36 months follow up. Contrary to the literary data (Chesebro 1983) coumarol plus small dose ASA did not result excessive bleeding and can be suggested for patients with prosthetic heart valve. Examination of both the prothrombin and the malondialdehyde ratio with study of platelet aggregation is recommended as laboratory control.
4
Vatsa, Richa, Sunesh Kumar, and Lalit Kumar. "To assess the role of addition of bevacizumab therapy to carboplatin and paclitaxel as frontline treatment of epithelial ovarian cancer." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685308.
Full textAbstract:
Introduction: Efforts are going on for development of new drugs for epithelial ovarian cancer (EOC). We assessed safety profile of bevacizumab, a VEGF receptor blocking antibody in treatment of EOC. Methods: We assigned women with EOC to carboplatin (area under curve, 5 or 6) and paclitaxel (175 mg/square meter of body-surface area), given every 3 weeks for 6 cycles, or to this regimen plus bevacizumab (15 mg/kilogram body weight), given concurrently every 3 weeks for 5 or 6 cycles and continued for 30 additional cycles. Primary outcome measures was safety profile of bevacizumab and secondary outcome was to see progression free survival (PFS). Results: Out of 30 patients, 10 were in Bevacizuma arm (Arm A) and 20 in conventional chemotherapy arm (Arm B). Haematological toxicity, GI perforation and proteinuria was similar in both. Other toxicities e.g. bleeding complication (p = 0.002) and hypertension (p = 0.04) was more in Arm A. PFS was similar in both arms; 24 months in Arm A and 22 months in Arm B (p = 0.565). 4 (40%) patients in arm A discontinued treatment, two (20%) because of disease progression after PFS of 9 and 6 months, two because of development of toxicity considered to be due to bevacizumab; of which one developed jejenal perforation and disease progression after PFS of 6 months and 1 because of development of persistent proteinuria of grade 3 after 18 months. Conclusion: Bevacizumab therapy does not improve PFS in EOC but increases toxicity spectrum of chemotherapy.
5
Blank, Christian U., Judith M. Versluis, Elisa A. Rozeman, et al. "Abstract 3412: 36-months and 18-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients - update of the OpACIN and OpACIN-neo trials." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-3412.
Full text
6
Shepardson, Dylan, Suzanne Marks, David P. Holland, et al. "The Cost-Effectiveness Of 3 Months Of Weekly, Directly-Observed Rifapentine Plus Isoniazid (3HP) Vs. 9 Months Of Daily, Self-Administered Isoniazid (9H) For The Treatment Of Latent Tuberculosis Infection." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a1500.
Full text
7
Spencer, Roy C., and Arnold Rivera. "Establishing the “Fitness for Use Criteria” for Pipe Line Variable Frequency Drives." In 1996 1st International Pipeline Conference. American Society of Mechanical Engineers, 1996. http://dx.doi.org/10.1115/ipc1996-1887.
Full textAbstract:
“Fitness For Use”[1] criteria are used to define project quality. This paper documents how to establish the “Fitness For Use” criteria for pipe line variable frequency drives (VFD’s). A Pipe Line VFD project’s life cycle process together with the technical requirements” determine its “fitness for use”. Effective definition and management of these “life cycle requirements”, therefore ensures a quality result. In summary, this paper documents how the “Fitness For Use Criteria” methodology was successfully used on the IPL Capacity Expansion Program to: (a) establish the project process; (b) engineer, procure, construct, commission and start-up the VFD systems; and (c) carry out training plus technically support the pipe line’s early operation phase. The Canadian section of IPL’s Line 13 is powered by eight pump stations containing five 3750 hp and three 6250hp, current source inverter (CSI)[2] based VFDs; this equipment was installed and commissioned in 1994, and has been in operation for 18 months.
8
AlSaud, Mohammed S., Abdulrahman D. AlDakhil, and Gys Van Zyl. "The Effect of Materials and Design Geometry on Tube Plugs at High Pressure Steam Super Heater." In ASME 2017 Pressure Vessels and Piping Conference. American Society of Mechanical Engineers, 2017. http://dx.doi.org/10.1115/pvp2017-66093.
Full textAbstract:
A high-pressure (HP) steam super heater located in the primary reformer of Ammonia Plant of Saudi Arabian Fertilizer Company (SAFCO) has ruptured twice in two different tubes, in 2009 and again in 2014. On both occasions, the repair was performed by removing and plugging the failed tube. In January 2015, the new plug that was installed in 2014 failed and led to an emergency shutdown. The older plug was found to be in good condition. An investigation was initiated to determine the reason for failure of one plug within nine months of operation while another was still in good condition after 6 years of operation. The failed plug was subjected to a metallurgical failure analysis where visual and stereoscopic inspection, scanning electron microscopy, metallographic examination, and chemical analysis were performed. The two plugs had different geometric designs, and thermal and static structural finite element analyses were performed to compare the 2009 and 2014 designs. Based on the outcome of the investigation, the cause of failure and the reason for the discrepancy in lifetimes of the two plugs was determined. This paper will present the conclusions of the metallurgical failure analysis and design review which was performed, and the improved repair design that was developed as a result of the investigation.
9
Tang, Xueqing, Lirong Dou, Ruifeng Wang, Alsadig Mohmoud Gabir, and Mouiz Hamza Musa. "Deeper Re-completions Exploited Bypassed Oil in Massive Heavy Oil Reservoir: Case Study." In SPE/AAPG Africa Energy and Technology Conference. SPE, 2016. http://dx.doi.org/10.2118/afrc-2582438-ms.
Full textAbstract:
ABSTRACT Fula field at Block 6, Sudan contains crude of 16.8 to 19 °API with in-situ viscosity of 497 cp in Bentiu formation. It was on production in March, 2004 and has produced 14% of original oil in place. Massive and unconsolidated sandstones inter-bedded with thin (3 to 13 ft) and discontinuous shales possess high horizontal and vertical permeabilities (2 to 9.53 Darcies). Lateral dimensions of shale bodies range from 1,000 to 2,000 ft. To extend oil production life with water-free, initial development strategy was to perforate the upper and more permeable zones (Perforations are 30% of entire zones) to obtain profitable productivity. After fieldwide water breakthrough, based on the studies of bypassed oil distribution, the following innovative deeper re-completions have been applied in high-water-cut wells (water cut more than 80%) to exploit the bypassed oil zones and new pay zones that have been missed below the existing productive zones. squeeze cement into the existing high-water-cut zones, located at the upper portion of entire pay zones. Those long wormholes communicating with aquifer caused by deep sanding should be cemented.perforate partially the lower portion of pay zones with optimal shot density. 30 to 40% of entire pay zones and shot density of 5 shots per foot are recommended. Perforation tunnel optimization can be run for concrete well conditions.Progressing Cavity Pumps operate at low frequencies less than 30 Hz to regulate proper pressure drawdown less than observed critical value of sanding from field tests and water coning. Field production data indicate that this workover campaign has achieved more than 2-fold oil gain and reducing water cut by 30 to 50% compared to previous water cuts of over 80%, also, water cut plus dynamic fluid level remain relatively stable over 6 months.
10
Okawa, Shinpei, Takeshi Hirasawa, Kazuhiro Tsujita, Toshihiro Kushibiki, and Miya Ishihara. "3D quantitative photoacoustic image reconstruction using Monte Carlo method and linearization." In Photons Plus Ultrasound: Imaging and Sensing 2018, edited by Alexander A. Oraevsky and Lihong V. Wang. SPIE, 2018. http://dx.doi.org/10.1117/12.2293229.
Full text